Sevsen KULAKSIZOĞLU, Banu SANCAK, Nazan GÜNEL, Uğur COŞKUN, Adem ÜNAL, Cemal ÇEVİK

Serum lipid-bound sialic acid concentration in patients with breast cancer at different clinical stages

Lipid bağlı sialik asilin kanserlerin teşhisinde, nüks ve metastazların aranmasında önemli bir marker olduğu ileri sürülmüştür. Meme kanseri tanısı koymada ve prognozun takibinde lipid bağlı sialik asit düzeylerinin ölçümünün yararlı olduğunu göstermek amacı ile bu çalışma yapılmıştır. Gereç ve Yöntem: Serum lipid bağlı sialik asit düzeyleri yeni tanı konulmuş ve henüz öpere olmamış 11 meme kanserli hasta, bir ay içinde radikal mastektomi yapılmış 12 hasta, remisyondaki 9 hasta ve sağlıklı 9 kişide ölçülmüştür. Lipid bağlı sialik asit Katopodis ve Stock tarafından sunulan yöntem ile ölçülmüştür. Bulgular: Serum lipid bağlı sialik asit düzeyleri remisyondaki hastalar hariç tüm gruplarda kontrol grubuna kıyasla anlamlı derecede yüksek bulunmuştur (p < 0,05). Sonuç: Bütün bu sonuçlar meme kanser tanısında, nüks ve operasyonun başarılı olup olmadığım takipte bu parametrenin yardımcı olabileceğini göstermektedir.

Farklı evrelerdeki meme kanserli olgularda serum lipid-bağlı sialik asid düzeyleri

Purpose: Sialic acid in serum has been proposed as a useful cancer marker and periodical determinations of sialic acid in patients with tumor might be a reliable marker of tumor progression. The aim of this study was to investigate whether lipid - bound sialic acid can be used as a tumor marker for distinguishing patients with breast cancer from healthy individuals. Methods: Serum lipid - bound sialic acid levels were determined in 11 breast cancer patients who have just been diagnosed and not yet operated on 12 breast cancer patients who had been operated within 1 month, 9 patients in remission and 9 healthy female individuals. Lipid bound sialic acid was determined by the method of Katopodis and Stock. Results: All groups of patients except 'patients in remission showed mean values of lipid - bound sialic acid levels higher than healthy controls (p

PDF

___

1. Dnistrian A, Schwartz M, Katapodis N, Fracchia A,Stock CC. Serum lipid - bound sialic acid as a marker in breast cancer. Cancer 1982; 50:1815-1819.
2. Hakomori S, Kannagi R. Glycosphingolipids as tumor- associated and differentiation markers. J Natl Cancer Inst 1983; 71: 231-251.
3. Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids. Cancer Res 1985; 45: 2405 - 2414.
4. Warren L, Fuhrer JP, Buck CA. Surface glycoproteins of normal and transformed cells: A difference determined by sialic acid and a growth - dependent sialyl transferase. Proc Natl Acad Sci 1972; 69: 1838- 1842.
5. Yogeeswaran G, Salk P. Metastatic potential is positively correlated with cell surface sialylation of cultured murine cells. Science 1981; 212: 1514- 1516.
6. Salvagno L, Ferrazzi E, Sileni VC, Maggi S, Tredese F,Bedendo C, Russo MP, Fiorentino MV, Ceriotti G. Lipid bound sialic acid in cancer patients. Tumori 1985; 71:127- 133.
7. Munjal D, Piçken J, Pritchard J. Combined measurement and significance of lipid - bound sialic acid and carcinoembryonic antigen in detection of human cancer. Diagn Immunol 1984; 2: 36 - 43.
8. Katapodis N, Hirshaut Y, Geller N, Stock CC. Lipid associated sialic acid test for the detection of human cancer. Cancer Res 1982; 42: 5270 - 5275.
9. Dunzendorfer U, Katapodis N, Dnistrian A. Stock CC,Schwartz M, Whitmore W. Plasma lipid bound sialic acid in patients with prostate and bladder cancer.Invest Urol 1981; 19: 194 - 196.
10. Erbil K, Jones J, Klee G. Use and limitations of serum total and lipid - bound sialic acid concentrations as markers for colorectal cancer. Cancer 1985; 55: 404 -409.
11. Schwartz PE, Chambers SK, Chambers KT, Gutmann J,Katapodis N, Foemmel R. Circulating tumor markers in the monitoring of gynecologic malignancies. Cancer 1987; 60: 353-361.
12. Pos O, van der Stelt ME, Woltink G - J, Nijsten MWN,van der Tempel GL, van Dijk W, Changes in the serum concentration of the glycoprotein and al -protease inhibitor in severely burned persons: Relation to interleukin - 6 levels. Clin Exp Immunol 1990; 82: 579 - 582.
13. van Dijk W, Pos O, van der Stelt E, Eap CB. Inflammation induced changes in expression and glycosylation of genetic variants of al - acid glycoprotein: Studies with human sera, primary cultures of human hepatocytes and transgenic mice.Biochem J 1991; 276: 343-347.
14. Katapodis N, Stock CC. Improved method to determine lipid bound sialic acid in plasma or serum. Res Commun Chem Pathol Pharmacol 1980; 30: 171-180
15. Yogeeswaran G. Cell surface glycolipids and glycoproteins in malignant transformation. Adv Cancer Res 1983; 38: 289-350.
16. Singhal A, Hakomori S. Molecular changes in carbohydrate antigens associated with cancer. Bioassays 1990; 12: 223-230.
17. Fingerhut R, van der Horst GTJ, Verheijen F, Conzelmann E. Degradation of gangliosides by the lysosomal sialidase requires an activator protein. Eur J Biochem 1992; 208: 623.
18. Warren L, Fuhrer JP, Buck CA. Surface glycoproteins of normal and transformed cells: A difference determined by sialic acid and a growth - dependent sialyl transferase. Proc Natl Acad Sci ( U.S.A ) 1972;69: 1838-1842.
19. Warren L, Buck CA, Truszynski GP. Glycopeptide changes and malignant transformation: a possible role for carbohydrate in malignant behaviour. Biochim Bophys Acta 1978; 516: 97-127.
20. Glick MC. Membrane glycopeptides from virus and the normal counterpart. Biochemistry 1979; 18: 2525-2532.
21. Evans IM, Hiey R, Murphy M, Bosman B. N - Acetylneurammic acid transferase activity with growth of R3230 AL mammary tumor in rats and relationship of the serum activity to tumor burden. Cancer Res 1980; 40: 3103-3111.
22. Henderson W, Kessel D. Alteration in plasma sialyl transferase levels in patients with neoplastic disease. Cancer 1977: 38: 1129-1134.
23. Ronquist G, Nov E. Serum sialyltransferase and fucosyltransferase activities in patients with bronchial carcinoma. Cancer 1983; 52: 1674-1683.
24. Lipton A, Harvey H, Delong S. Glycoproteins and human cancer: I. Circulation levels in cancer serum. Cancer 1979; 43: 1766-1771.
25. Dnistrian A, Schwartz M. Lipid - bound sialic acid as a tumor marker. Ann Clin Lab Sci 1983; 13: 137-142.